Leo's Tralokinumab Poised For US Launch In 2021

 
• By Jessica Merrill
  
SC2007_Second Place_1457882090_1200.jpg
Leo's tralokinumab is poised to be the second biologic to market for atopic dermatitis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapy Areas